The drug, elinzanetant, is expected to be available in the United States beginning in November under the brand name Lynkuet, ...
More than two years after the mpox outbreak in the U.S. was declared over, a new crop of cases in California has infectious ...
2hon MSN
BiTE-based immunotherapy strategy could point the way to a breakthrough for ovarian cancer patients
Results of a study led by researchers at Roswell Park Comprehensive Cancer Center show that combining two types of immunotherapy—engineered T cells that secrete bispecific T cell engagers (BiTEs) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback